Summary & Overview
CPT 96401: Chemotherapy Administration, Subcutaneous or Intramuscular
CPT code 96401 covers the administration of non-hormonal anti-neoplastic chemotherapy by subcutaneous or intramuscular injection, a critical service in oncology practices nationwide. This code is widely recognized by major payers, including Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare, reflecting its importance in cancer treatment protocols. The publication provides a comprehensive overview of the clinical context for 96401, including its role in office-based chemotherapy administration and its relevance to hematology and oncology specialties. Readers will gain insight into payer coverage, typical sites of service, and related coding practices. The summary also highlights associated modifiers and taxonomies, as well as common ICD-10 diagnoses linked to this procedure, such as multiple myeloma in various stages. Additionally, the article outlines related CPT codes for comparison, offering a broader perspective on chemotherapy administration coding. This resource is designed to inform healthcare professionals, billing specialists, and policy analysts about the key aspects of 96401, supporting accurate reporting and understanding of its place in oncology care.
CPT Code Overview
CPT code 96401 is used to report the administration of chemotherapy via subcutaneous or intramuscular injection for non-hormonal anti-neoplastic agents. This procedure is a core component of oncology care, enabling the delivery of cancer treatment in a controlled clinical setting. The typical site of service for this code is the office, designated as Place of Service 11. Chemotherapy administration is essential for patients undergoing treatment for various malignancies, and accurate coding ensures proper documentation and reimbursement for these services.
Clinical & Coding Specifications
Clinical Context
A patient diagnosed with multiple myeloma, such as with diagnosis codes C90.00, C90.01, or C90.02, presents to the oncology office (Place of Service 11) for scheduled chemotherapy treatment. The provider, typically a hematology or oncology specialist, prepares and administers a non-hormonal anti-neoplastic agent via subcutaneous or intramuscular injection. The clinical workflow includes patient assessment, preparation of the chemotherapy drug, administration of the injection, and post-administration monitoring for adverse reactions. If a significant, separately identifiable evaluation and management service is performed on the same day, modifier 25 may be appended to the E/M code.
Coding Specifications
- Modifier
25: Used when a significant, separately identifiable evaluation and management service is performed on the same day as the chemotherapy administration. This modifier is appended to the E/M code, not the chemotherapy administration code.
| Provider Taxonomy Code | Specialty Name |
|---|---|
207RH0003X |